NRP1 and breast carcinoma: Experimental studies have proven that FOXO3a interacts with the miR-29b/miR-338 promoter to inhibit breast cancer cell proliferation, while miR-29b and miR-338 target the 3’-UTR of VEGF-A and NRP1, respectively, to oppress breast cancer cell growth.